Lantheus Reports Strong Q1 GAAP EPS, Advances Key Products Despite PDUFA Delay
Summary
Lantheus Holdings reported its first quarter 2026 financial results, with GAAP fully diluted earnings per share significantly increasing by 76.5% to $1.80, and worldwide revenue growing 1.2% to $377.3 million. However, adjusted fully diluted EPS saw a 4.6% decrease to $1.46. The company also announced FDA approval for PYLARIFY TruVu, a new formulation of its market-leading PSMA PET imaging agent, and tentative FDA approval for PNT2003, a potential radioequivalent for GEP-NETs. Conversely, the FDA extended the PDUFA date for LNTH-2501 by three months to June 29, 2026, to review manufacturing-related information. Full-year 2026 financial guidance for revenue and adjusted EPS was reiterated. This mixed report, with strong GAAP performance alongside a dip in adjusted earnings and a blend of positive product approvals and a regulatory delay, provides a complex picture for investors. Traders will closely watch the commercial rollout of PYLARIFY TruVu, the path to full approval for PNT2003, and the final FDA decision on LNTH-2501 in June.
At the time of this announcement, LNTH was trading at $89.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $47.25 to $108.91. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.